Placeholder Banner

Global “SHARE” Program for COVID could provide global protection against pandemic and create American jobs

BIO puts Forward possible solution to impasse over IP

May 4, 2021
Media Contact
JG
2027471281

Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), sent a letter to President Joe Biden yesterday suggesting the establishment of a COVID Global Strategy for Harnessing Access Reaching Everyone (SHARE) Program, to be implemented immediately.

The letter, which is chalked full of policy solutions, is a response to the “worsening COVID crises in India, Brazil and elsewhere.”

The Global SHARE Program would consist of three parts:

1) Ensuring sufficient global supply of vaccines;

2) Ensuring safe and expeditious global access to vaccines and therapeutics; and

3) Ongoing Efforts to strengthen and support healthcare systems in low-and middle-income countries in addressing COVID.

Dr. McMurry-Heath writes: ”In the past year, over 950 research and development projects to address COVID have been launched, 70% of them by small and medium sized companies. These efforts can only truly be successful if they result in patients around the world receiving safe, effective treatments and vaccines. Clearly further action is needed if we are to achieve true global social justice in addressing the COVID crisis.”

Read the letter and BIO’s detailed policy suggestions here.

Discover More
 USTR this week released its 2022 Special 301 Report. BIO, after reviewing the report, released the following statement: We welcome USTR’s efforts to address IP-related concerns for U.S.-based biotech enterprises in China, especially…
John Murphy, Chief Policy Officer at the Biotechnology Innovation Organization (BIO), released the following statement regarding reports of a proposed deal on a Covid-19 vaccine intellectual property rights waiver: “While we have seen the reported…
“Retaliation of this kind will only serve to isolate Russian science and technology from the international mainstream. At the end of the day those who will be most hurt by this decision will not be innovative global companies, but Russian patients,…